Market Place
Sourcing Support
Milestone Pharmaceuticals to Host Investor KOL Event
24 Sep 2024 //
GLOBENEWSWIRE
Milestone Partner Ji Xing Reports Positive Ph 3 Results For Etripamil In PSVT
07 Sep 2024 //
GLOBENEWSWIRE
Milestone Partner Ji Xing Pharma, Positive Result of Ph 3 Study in PSVT in China
07 Sep 2024 //
GLOBENEWSWIRE
Milestone Pharmaceuticals Adds Joseph Papa To Board
04 Sep 2024 //
GLOBENEWSWIRE
Milestone® Pharmaceuticals to Present Data on Etripamil at the ESC Congress 2024
26 Aug 2024 //
GLOBENEWSWIRE
Milestone Pharma Reports Q1 2024 Results, Regulatory And Corporate Update
13 May 2024 //
GLOBENEWSWIRE
Milestone: Etripamil Data At Heart Rhythm, Stanford, ISPOR 2024
02 May 2024 //
GLOBENEWSWIRE
Milestone Pharmaceuticals to Present Data on Etripamil at the Preventative CNS
17 Apr 2024 //
GLOBENEWSWIRE
Milestone Announces Etripamil Data at The American College of Cardiology Meeting
08 Apr 2024 //
GLOBENEWSWIRE
Milestone to Present Data on Etripamil at the Association Annual Conferences
01 Apr 2024 //
GLOBENEWSWIRE
Milestone Announces Resubmission of NDA for Etripamil for Treatment in PST
28 Mar 2024 //
GLOBENEWSWIRE
Milestone Pharmaceuticals Announces Plan to Resubmit NDA for Etripamil
26 Feb 2024 //
GLOBENEWSWIRE
Milestone Pharma Receives Refusal to File Letter from FDA for NDA for Etripamil
26 Dec 2023 //
GLOBENEWSWIRE
Milestone Pharma Presents Positive Results from Phase 2 Study of Etripamil
11 Nov 2023 //
PR NEWSWIRE
Milestone Pharmaceuticals to Host Investor and Analyst Webcast
07 Nov 2023 //
PR NEWSWIRE
Milestone Announces Submission of NDA to the U.S. FDA for Etripamil
24 Oct 2023 //
PR NEWSWIRE
Milestone nnounces Publication of Results from Ph3 RAPID Trial of Etripamil
20 Jun 2023 //
PR NEWSWIRE
Milestone Pharma Progresses Clinical and Regulatory Activities for Etripamil
06 Mar 2023 //
PR NEWSWIRE
Selagine Enters into a Collaborative Agreement with Grifols
06 Mar 2023 //
PR NEWSWIRE
Milestone Pharma to Present Data from PIII NODE-302 Study of Etripamil
30 Apr 2022 //
PRNEWSWIRE
Milestone Pharma to Host Virtual Key Opinion Leader Event on Etripamil
14 Apr 2022 //
PRNEWSWIRE
Milestone Announces First Patient Enrolled in RAPID, a Pivotal Ph 3 Etripamil
18 Nov 2020 //
PRESS RELEASE
Milestone Announces Regulatory Guidance &Updated Clinical DEV Plan for Etripamil
22 Jul 2020 //
PRNEWSWIRE
Milestone Announces Topline Results from First-of-its-kind Phase 3 NODE-301
23 Mar 2020 //
PR NEWSWIRE
Milestone Pharmaceuticals Announces Pricing of Upsized Initial Public Offering
09 May 2019 //
PR NEWSWIRE
Four biotechs haul in $303M+ from a fresh burst of IPOs
09 May 2019 //
ENDPTS
Milestone Pharmaceuticals Announces $80 Million Private Financing
26 Oct 2018 //
PR NEWSWIRE
Milestone Pharma grabs an $80M round
25 Oct 2018 //
ENDPTS
Milestone Pharma preps a leap into Ph3 cardio study $55M round backed by Novo
02 Aug 2017 //
ENDPTS
